Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial
pharmafile | July 26, 2016 | News story | Research and Development | Celgene, Revlimid, lymphoma
Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma but found no benefit versus placebo in terms of overall survival.
In the REMARC study, Revlimid was evaluated in diffuse large B-cell lymphoma patients responding to first-line Mabthera (rituximab) plus CHOP chemotherapy induction therapy. The trial was co-sponsored by the Lymphoma Academic Research Association (LYSARC).
Revlimid has had multiple successes to date, most recently receiving approval from the EU to treat a rare form of non-Hodkin’s lymphoma. It has also been approved in several multiple myeloma indications.
In the study, Revlimid achieved the primary endpoint of a statistically significant improvement in progression-free survival but failed to provide any benefit in overall survival. Based on these results, Celgene does not currently plan to seek approval for Revlimid in diffuse large B-cell lymphoma.
Michael Pehl, president of haematology and oncology at Celgene, says: “We are continuing to partner with the Lymphoma Study Association to complete the analyses of the REMARC study. We remain committed to finishing the four ongoing Phase III trials evaluating Revlimid and are confident about its potential as a treatment option across different settings in lymphoma.”
Shares at Celgene fell 3.2% in after-hours trading, at the time of writing, following the news. The company are expected to publish their financial results for Q2 2016 later this week.
Sean Murray
Related Content
Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …
National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health …
AstraZeneca shares positive interim results from phase 3 lymphoma trial
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 …
